Company ProfilePremium

CVS Health Corp

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
CVS Health Corp - Company showcase

Year Founded & Workforce

1996

300,000 Employees

CVS Health Corp logo

CVS Health Corp Employee Contacts

367 verified contactsNames, job titles, seniority and locations

View Employee Contacts

CVS Health Corp Overview

The Company has reported "approximately 300,000" or "more than 300,000" colleagues for each year in the table, so the disclosed figure is not sensitive enough to reveal the underlying trend. Third-party workforce analytics (Revelio Labs, March 2026) estimate 300,359 employees, down 0.8% year over year and down approximately 4.0% versus 2023, with roughly 93.3% of headcount in the United States, 1.4% in India and 0.5% in Canada.

Positioning statement (analyst characterisation, ~150 words). CVS Health is the only US healthcare company that simultaneously owns the insurance risk, the pharmacy benefit, the retail dispensing footprint and a primary-care delivery arm at national scale. Its structural claim is that owning all four rungs of the pharmaceutical and benefit value chain lets it capture margin that competitors must share, and lets it steer patients — 85% of Americans live within ten miles of a CVS Pharmacy. In practice the Company spent 2023 through 2025 discovering that vertical integration also concentrates risk: Medicare Advantage cost trend, Part D redesign, PBM regulatory scrutiny and a failed clinic-expansion thesis all landed on the same balance sheet at once. FY2025 revenue reached a record $402.1 billion while GAAP net income fell to $1.8 billion after a $5.7 billion goodwill impairment. The 2026 story is margin repair, not growth: management is guiding to at least $414 billion of revenue and $7.90–$8.10 of adjusted EPS, with revenue essentially flat and all the earnings improvement coming from Aetna's underwriting recovery.


The Company's own description

The FY2025 Form 10-K opens with the Company's self-characterisation: CVS Health is a leading health solutions company building a world of health around every consumer it serves and connecting care so that it works for people wherever they are. As of 31 December 2025 it operated approximately 9,000 retail locations, more than 1,000 walk-in and primary care medical clinics, and a pharmacy benefits manager with approximately 87 million plan members and expanding specialty pharmacy solutions. It serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company states it is creating new sources of value through an integrated model that allows expansion into personalised, technology-driven care delivery and health services.

The stated ambition, adopted in late 2025 and reproduced in the 2026 proxy statement, is to be America's most trusted health care company, with a purpose of simplifying health care one person, one family and one community at a time, and four stated values: we care; we innovate with purpose; we are accountable; we prioritise safety and quality.

Independent characterisation

CVS Health is best understood as three distinct P&Ls bolted onto a shared consumer footprint, plus a fourth structurally loss-making corporate segment.

The insurance business (Aetna) is a conventional managed-care underwriter. It earns a premium spread — the difference between the premium received and the medical costs incurred — and its economics are governed by the medical benefit ratio (MBR). It sells to employers, to individuals via Medicare, and to state Medicaid agencies. It is the most volatile earnings stream in the enterprise and the one that broke in 2024: FY2024 segment adjusted operating income collapsed to $307 million on $130.7 billion of revenue. FY2025 recovered to $2.9 billion, and H1 2026 alone delivered $5.5 billion.

The pharmacy benefit business (CVS Caremark) is a spread-and-fee intermediary. It processes claims, negotiates rebates with manufacturers through the Zinc group purchasing organisation, manages formularies, and operates mail and specialty pharmacies. Its revenue is enormous and its margin thin: FY2025 Health Services gross margin was 5.2% and adjusted operating margin 3.8%. The business model has been under sustained regulatory attack; the pricing architecture is migrating from rebate-driven spread toward transparent cost-plus constructs (CVS CostVantage, CVS CaremarkTrueCost) partly by choice and partly under duress.

The retail pharmacy business (CVS Pharmacy) is a dispensing and convenience-retail hybrid. Pharmacy was 82.9% of segment revenue in FY2025, up from 78.9% in FY2023, meaning the front store is shrinking as a share of the mix. Gross margin here is the highest of the three at 18.5% for FY2025, but reimbursement pressure is relentless and the Company completed a transition of its commercial, third-party discount, Medicare and Medicaid books to cost-based reimbursement during 2025.

Health care delivery — Oak Street Health, Signify Health, MinuteClinic — sits inside the Health Services segment and is the piece that has not worked. The $5.7 billion goodwill impairment recorded in FY2025 was taken against the Health Care Delivery reporting unit, and the Company recorded a further $83 million charge for the planned closure of certain Oak Street Health clinics in 2026. Management's Investor Day framing is telling: the target for this business is "driving towards breakeven with a path to sustained profitability" — an admission that the 2023 acquisitions have not yet earned their cost of capital.

Revenue model composition

Revenue line (USD Mn)FY2024FY2025
Products231,521249,908
Premiums122,896134,751
Services16,23915,175
Net investment income2,1532,233
Total revenues372,809402,067

CVS does not sell software subscriptions or licence intellectual property at scale. Its revenue is essentially three buckets, disclosed on the face of the income statement:

Source: Q4/FY2025 earnings release, Exhibit 99.1, 10 February 2026.

Products — overwhelmingly prescription drugs — were 62.2% of FY2025 revenue. Premiums were 33.5%. Services, which includes PBM administrative fees, Signify Health evaluations and Aetna ASC fees, were only 3.8% and are declining in absolute terms (down 6.6% in FY2025), a direct consequence of PBM client price improvements and the exit of the Accountable Care businesses.

Value chain position and customer types

SegmentWho paysNature of relationship
Health Care BenefitsEmployers, individuals, CMS, state Medicaid agencies, federal employee programmesAnnual contracts; CMS capitation adjusted for risk and star ratings
Health ServicesEmployers, insurers, unions, government employee groups, health plans, PDPs, Managed Medicaid plans, CMS, 340B covered entities, patientsMulti-year PBM contracts with annual repricing; capitated value-based payor contracts for Oak Street
Pharmacy & Consumer WellnessPBMs, managed care organisations, government programmes, commercial employers, third-party payors, and cash-paying consumersPer-script reimbursement; retail transactions

CVS occupies the intermediary and last-mile positions in the US pharmaceutical value chain. It does not manufacture drugs (with the narrow exception of Cordavis, which co-produces and commercialises biosimilars). It does not distribute at wholesale — that is McKesson, Cencora and Cardinal Health, with whom CVS partners through the 50/50 Red Oak Sourcing generic sourcing joint venture with Cardinal Health.

Customer types by segment:

Concentration: Health Care Benefits revenue from the federal government was approximately 20% of consolidated total revenues in each of 2023, 2024 and 2025. CMS contracts for Medicare-eligible individuals represented approximately 79% of federal-government revenue in 2025, up sharply from 74% in 2024 and 73% in 2023 — a meaningful increase in single-counterparty dependency. No single Pharmacy & Consumer Wellness payor accounted for 10% or more of consolidated revenue in any of 2023–2025.

Strategy

Stated strategy — verbatim themes from the FY2025 Form 10-K

The Company states its ambition is "to be America's most trusted health care company" and its purpose is "to simplify health care one person, one family and one community at a time." Its strategy is described as "focused on simplifying health care experiences, improving engagement, lowering costs and delivering better health outcomes." It expects to create sustainable shareholder value by delivering "best-in-class execution, transforming consumer experiences, being the partner of choice and harnessing enterprise capabilities, enabled by innovation and capital stewardship."

The 2025 Investor Day framed the same four pillars: deliver best-in-class execution; transform consumer experiences; be the partner of choice; harness unique enterprise capabilities.

Joyner's framing at Investor Day: "In my nearly 40 years at the Company, I have seen our businesses and our industry find ways forward, always with consumer needs first. Our obligation is to ensure that CVS Health is best positioned to do the most good for the most people for the next 40 years."

Business-unit strategic mandates (Investor Day, 9 December 2025)

BusinessStated mandate
AetnaStrong earnings growth powered by return to target margins
CVS CaremarkWinning and retaining business while delivering attractive margins
CVS PharmacySustaining earnings while serving as the front door to health care
Health Care DeliveryDriving towards breakeven with a path to sustained profitability

The asymmetry is instructive. Only Aetna is asked for growth. Caremark is asked to defend share. Pharmacy is asked to sustain, not grow. Health Care Delivery is asked to stop losing money. This is a repair plan, not an expansion plan.

Financial targets and guidance

Guidance metric2026 initial (Dec 2025)Feb 2026May 2026Aug 2026 (current)
Total revenues (USD bn)at least 400.0at least 400.0at least 405.0at least 414.0
GAAP diluted EPS (USD, low)—5.946.246.84
GAAP diluted EPS (USD, high)—6.146.447.04
Adjusted EPS (USD, low)7.007.007.307.90
Adjusted EPS (USD, high)7.207.207.508.10
Cash flow from operations (USD bn)at least 10.0at least 9.0at least 9.5at least 11.5
Weighted average diluted shares (millions)—1,285—1,289

Medium-term target: a mid-teens adjusted EPS compound annual growth rate through 2028, committed at the December 2025 Investor Day. Measured from the FY2025 base of $6.75, a 15% CAGR implies roughly $10.3 billion of adjusted income and adjusted EPS near $10.30 by 2028. The current 2026 guidance midpoint of $8.00 represents 18.5% growth — ahead of the mid-teens trajectory in year one.

At Q1 2026 management guided Health Care Benefits full-year adjusted operating income to approximately $4.00–$4.34 billion, an increase of $420 million versus prior guidance, reflecting favourable prior-year development.

Strategic initiatives announced in the last 24 months

DateInitiativeDetail
Q3 2024Enterprise restructuring planApproximately $1.2 billion of charges; store impairments, corporate workforce optimisation, discontinuation of non-core assets; decision to close additional retail stores in 2025
Oct–Nov 2024Leadership reconstructionJoyner as CEO; Nelson to Aetna; Shah to Group President; four new directors
Q1 2025Exit of Accountable Care businessesMSSP operations sold March 2025; ACO REACH wound down; $288 million pre-tax loss
2,025Cost-based reimbursement transitionCompleted across Commercial, Third-Party Discount, Medicare and Medicaid at CVS Pharmacy; cost-based pricing models performing in line with expectations
2,025Bundled prior authorisationAligned standard care pathways that previously required multiple prior authorisations into a single authorisation; expanded in 2026 to conditions including IVF
2,025Prior authorisation turnaround commitmentMore than 95% of eligible Aetna prior authorisations approved within 24 hours, many instantaneously
Q3 2025Rite Aid asset acquisitionsPrescription files acquired; approximately 9 million patients and more than 3,500 colleagues absorbed
Sept 2025Omnicare Chapter 11 and deconsolidationExit from long-term care pharmacy; $483 million gain on deconsolidation; approximately $1.9 billion tax benefit
2,025Biosimilar formulary strategyMore than $1.5 billion in client savings delivered through biosimilar adoption
Nov 2025Governance restructureJoyner appointed Chair; Public Policy and External Affairs Committee established
Dec 2025Investor Day and long-term targetsMid-teens adjusted EPS CAGR through 2028; new ambition, purpose and values adopted
Jan 2026Individual public exchange exitAetna exited all states in which it operated on the ACA Public Exchanges
2,026Agentic AI deploymentSecure agentic AI call-centre platform for Aetna and Caremark members and providers; reported 20–30% reduction in call volume and complex-call handling time
Q2 2026Aetna Claims Assist Manager, generation 2AI-powered agentic claims advisor; over 20% reduction in processing time for complex claims requiring manual review
2,026Small-format pharmacy locationsNew compact store format to extend community access
5 Aug 2026GLP-1 access programme and Eli Lilly collaboration$29 MinuteClinic virtual visit with no membership or recurring fee; transparent app-based pricing for Zepbound and Foundayo from early Q4 2026 with same-day pickup at approximately 9,000 locations; participation in the CMS Medicare GLP-1 Bridge programme through 31 December 2027 at $50 per month for eligible beneficiaries; commercial formulary expansion of GLP-1 options
2,026Pet prescription dispensingCVS begins filling prescriptions for dogs and cats

Sustainability and ESG commitments

Covered in detail at Section 20. In summary: SBTi-validated net zero across the value chain by 2050 (direct operations by 2048); 47% absolute reduction in Scope 1, 2 and Scope 3 purchased goods and services emissions by 2030 from a 2019 base; 50% renewable electricity by 2040; Healthy 2030 framework organised around Healthy People, Healthy Business, Healthy Community and Healthy Planet.

Products & Services

Health Care Benefits segment (Aetna)

OfferingDescriptionTarget customerScale / scope (FY2025)Pricing model
Commercial Medical — POS, PPO, HMO, IndemnityFull-spectrum employer medical plans on Insured and ASC basesLarge multi-site national, mid-sized and small employers; individuals; expatriates18.8 million Commercial members (3.4m Insured, 15.4m ASC) at 31 Dec 2025Fixed premium set in advance for Insured; fixed annual fee for ASC
Health Savings Accounts and consumer-directed health plansPOS/PPO with deductible plus accumulating benefit account funded by sponsor and/or memberEmployers seeking cost-shifting designs—Premium plus account contributions
Medical stop-loss insuranceAssumes risk for large individual claims and/or aggregate loss above a pre-set annual thresholdSelf-insured employers—Attachment-point priced premium
Aetna DentalDental plans complementing medicalEmployers, individuals—Premium
Aetna VisionVision productsEmployers, individuals—Premium
Behavioural health and employee assistance programmesBehavioural products and EAPEmployers—Premium / per-employee fee
Aetna Medicare Advantage (HMO and PPO)Enhanced-benefit Medicare replacement plans under annual CMS contracts; national PPO available to qualifying employer groupsMedicare-eligible individuals and retiree groups4.27 million members; offered in 44 states and Washington DCCMS capitation adjusted for demographics, risk score and star rating; supplemental member premium in some plans
Aetna Medicare SupplementCoverage for deductibles and coinsurance not covered by Original MedicareMedicare beneficiaries1.20 million members; offered in 49 states and DCState-regulated premium
SilverScript / Aetna Medicare Part D PDPNational standalone prescription drug planAll Medicare-eligible individuals4.04 million members at 31 Dec 2025 (down from 4.88m); offered in all 50 states and DCCMS payment plus member premium; risk-sharing corridors with CMS; participating in the CMS PDP premium stabilisation demonstration in 2025 and 2026
Medicaid and CHIP managed careHealth care management for Medicaid and CHIP eligibles under multi-year state contractsState agencies2.33 million members; offered on Insured or ASC basis in 15 statesFixed monthly per-member rate set by each state; actuarially sound requirement
Dual Eligible Special Needs Plans (Duals)Coordinated coverage for beneficiaries eligible for both Medicare and MedicaidDual-eligible individuals—Rate set by CMS in partnership with the state
Individual public exchange plansACA marketplace Insured plans sold direct to consumersIndividualsDiscontinued — the Company exited all states in which Aetna operated on the Public Exchanges effective January 2026—
Federal Employees Health Benefits / FEDVIPHMO and consumer-directed medical and dental plans for federal employeesUS federal government—Premium subject to federal audit and retroactive adjustment
Aetna Claims Assist Manager (CAM), 2nd generationAI-powered agentic claims advisor platform; reduces processing time by over 20% for complex claims requiring manual reviewProviders and internal claims operationsLaunched Q2 2026Internal capability; no direct pricing
Bundled prior authorisationCombines multiple prior authorisations for a condition pathway (e.g. IVF) into a single authorisation covering both medical care and required drugsProviders and membersIntroduced 2025; expanded 2026Internal capability
Provider networkContracted physicians, hospitals, laboratory, imaging, urgent care and freestanding facilities—Approximately 2.0 million participating providers at 31 Dec 2025Negotiated fee schedules and risk-sharing arrangements

Quality accreditation: Aetna Life Insurance Company holds nationwide NCQA PPO Health Plan accreditation; all eligible Commercial HMO and ALIC PPO members were in NCQA-accredited plans at 31 December 2025; the Company holds NCQA Credentials Verification Organization certification for all options and URAC CVO accreditation. More than 81% of Medicare Advantage members were in plans rated at least 4.0 stars for 2026, and more than 63% in 4.5-star plans — down from 88% at 4.0+ stars for 2025, a material deterioration that will affect 2027 bonus payments.

Health Services segment (CVS Caremark and health care delivery)

OfferingDescriptionScale / detail
Plan design offerings and administrationBenefit design consultancy, eligibility, claims adjudication, performance reviews (annual, quarterly, sometimes monthly)Approximately 87–88 million plan members
Formulary managementTemplate formularies curated by the CVS Caremark National Pharmacy and Therapeutics Committee — an independent panel of physicians, pharmacists and medical expertsBiosimilar adoption delivered more than $1.5 billion of client savings (2025 proxy disclosure)
Retail pharmacy network managementNational contracted networkApproximately 63,000 retail pharmacies: approximately 34,500 chain (including CVS locations) and approximately 28,500 independent, across the US, Puerto Rico, DC, Guam and the US Virgin Islands
Maintenance ChoiceLets eligible members fill maintenance prescriptions by mail or at a CVS retail store at the same price as mail orderReported within pharmacy network revenue
Specialty ConnectSpecialty prescriptions picked up at retail but adjudicated as specialtyReported within mail and specialty revenue
Specialty ExpediteInterconnected onboarding solution for specialty medicationsDigital workflow platform
Mail order and specialty mail order pharmaciesMaintenance medication fulfilment and advanced therapies for chronic/genetic conditionsURAC Mail Service and Specialty Pharmacy accredited; substantially all specialty mail pharmacies also accredited by The Joint Commission and ACHC, including Pharmacy Compounding Accreditation Board certification and a distinction in Rare Diseases and Orphan Drugs
Retail specialty pharmacy storesPhysical specialty dispensing locationsReported in Pharmacy & Consumer Wellness fulfilment
Clinical services — utilisation management, medication management, quality assurance, adherence and counsellingProgrammes to reduce inappropriate utilisation and improve adherenceNCQA and URAC accredited UM programme
Pharmacy Advisor and Drug Savings ReviewDigital, telephonic, in-person and provider-facing outreach for chronic-disease membersCore medication support products
CVS Weight ManagementOptimises GLP-1 utilisation with label-recommended lifestyle support and coaching; addressing new indications such as cardiovascular diseaseExtended in 2026 to new indications
NovoLogixOnline preauthorisation tool identifying cost-saving opportunities for specialty drugs billed under the medical benefitMedical benefit management
Zinc Health ServicesGroup purchasing organisation negotiating pharmaceutical pricing and rebates on behalf of participantsSubject to the July 2026 FTC consent order requirements
CordavisWholly-owned subsidiary that works directly with manufacturers to commercialise and/or co-produce biosimilarsLaunched 2023
CVS CostVantage / CVS CaremarkTrueCostCost-plus retail reimbursement model and transparent PBM pricing modelAnnounced December 2023; retail cost-based transition across Commercial, Third-Party Discount, Medicare and Medicaid completed in 2025
Health Engagement EngineProprietary clinical algorithm layer converting pharmacy data into interventions at points of careCloud-native; deployed across retail, mail, specialty and call centres
OfferingDescriptionScale (FY2025)
Oak Street HealthRetail-format community-based value-based primary care centres for Medicare-eligible patients; full financial risk under capitated payor contracts246 centres across 27 states; care for approximately 500,000 patients; strategic value-based relationships with over 25 payors including each of the top 5 national payors by Medicare Advantage patients; certain clinic closures planned for 2026
CanopyCustom-built proprietary clinical and operational workflow platform underpinning the value-based care modelEnterprise platform
Signify HealthMobile network of credentialed providers conducting in-home health evaluations and select diagnostic services, virtually or at provider facilitiesMore than 3.5 million in-home evaluations in 2025; contracts with 46 health plans including 24 of the 50 largest Medicare Advantage plans; Medicare Advantage plans are approximately 85% of volume; supported more than 500,000 reconnections to care in 2025
MinuteClinicNurse practitioner and physician assistant staffed retail clinics, plus virtual careMore than 800 locations; virtual care available in nearly all states
MinuteClinic virtual weight-loss visit24/7 online clinician consultation that can initiate GLP-1 therapy where clinically appropriate, with follow-ups for dose optimisation, adverse-effect support and monitoringRepriced to $29 with no membership or recurring fee, announced 5 August 2026
ACO REACH and Medicare Shared Savings Program enablementProvider enablement under CMS programmesDiscontinued — MSSP sold March 2025; ACO REACH wound down; $288 million aggregate pre-tax loss

Pharmacy benefit management

Health care delivery

Pharmacy & Consumer Wellness segment (CVS Pharmacy)

OfferingDescriptionScale / detail (FY2025)
CVS Pharmacy retail dispensingPrescription dispensing across the national store estate, including pharmacies located inside Target storesApproximately 9,000 retail locations; 1.8 billion prescriptions filled on a 30-day equivalent basis; approximately 28.5% of all US retail pharmacy prescriptions dispensed; more than 29% retail script share cited in the 2026 proxy
Small-format pharmacy-focused locationsNew compact store format unveiled in 2026 to extend community accessAnnounced Q1 2026
Front store merchandiseOver-the-counter drugs, consumer health, beauty, personal care and general merchandise17.1% of segment revenue, down from 21.1% in FY2023
Proprietary brandsApproximately 4,500 proprietary-brand SKUs available only at CVSApproximately 20% of front store revenue in 2025
ExtraCareLoyalty card programme with automatic sale pricing, customised coupons and ExtraBucks rewardsOne of the largest US retail loyalty programmes
ExtraCare PlusPaid subscription membership with a benefits suite plus a promotional reward redeemable for future goods and servicesSubscription fee
Vaccination administrationIn-store immunisation, scheduled via CVS.com with digital recordsSeasonal peak in Q1 and Q4
Diagnostic testing and pharmacy patient care programmesAncillary clinical services delivered at the pharmacy counterIncluded in segment services revenue
Coram infusion and enteral nutrition servicesHome and ambulatory infusion branchesBranch network; excluded from same-store metrics
Compounding pharmaciesSpecialised preparationIncluded in retail specialty operations
Specialty and mail order fulfilment servicesFulfilment and patient management provided to the Health Services segmentHealth Services pays an administrative service fee to this segment
CVS.com and CVS Health appOnline retail pharmacy, refill management, scheduling, digital savings tools; from early Q4 2026 will display transparent Zepbound and Foundayo pricing including cash-pay options with same-day pickupDigital sales included in same-store metrics
340B servicesContract pharmacy arrangements with covered entitiesAvailable at retail locations
Medicare GLP-1 Bridge programme participationCMS programme running through 31 December 2027 allowing eligible Medicare beneficiaries to access certain GLP-1 medications for $50 per monthNational, subject to state regulation
Pet prescription dispensingFilling prescriptions for dogs and catsAnnounced August 2026
Omnicare long-term care pharmacyDistribution and consulting to long-term care facilitiesDeconsolidated September 2025; assets subsequently approved for sale to GenieRx Holdings for a reported $250 million

Cross-enterprise

OfferingDescription
Red Oak Sourcing, LLC50/50 generic pharmaceutical sourcing joint venture with Cardinal Health, Inc. Red Oak sources and negotiates generic supply contracts for both parents but does not own or hold inventory.
CVS Health VenturesCorporate venture capital arm investing in health technology and services.
Agentic AI call centre platformDeployed in 2026 to simplify and streamline call-centre interactions for Aetna and Caremark members and providers on a secure platform; the Company reports reducing overall call volume and the handling time for certain complex calls by 20–30%.
WeCARE WorkflowProprietary pharmacy workflow tool prioritising work, facilitating prescriber outreach and integrating clinical programmes.
AI pharmacist and nurse toolsAI adherence-identification tools for pharmacists; AI support returning approximately 90 minutes per day to Aetna nurses.

Financial Narrative

Income statement

Revenue CAGR FY2021–FY2025: 8.31% (computed). CVS has compounded revenue at more than 8% while destroying per-share earnings, because the incremental revenue is low-margin Government premium and drug-mix inflation, not profit.

Commentary on trends and inflections.

FY2021 was the peak of the post-Aetna model: Operating margin of 4.52% and net margin of 2.71% have not been approached since. COVID-19 testing and vaccination volumes flattered the retail segment.

FY2022 was the first litigation shock: GAAP operating income halved on $5.8 billion of opioid litigation charges and an approximately $2.5 billion loss on assets held for sale for the long-term care business. Adjusted EPS nonetheless rose to $8.69, demonstrating how far the adjusted measure had drifted from GAAP reality.

FY2023 was the acquisition year: Signify Health and Oak Street Health closed within five weeks of each other, adding roughly $18.6 billion of purchase price and pushing goodwill from $78.2 billion to $90.7 billion. GAAP results recovered because the 2022 charges did not repeat, not because operations improved: adjusted operating margin was already compressing.

FY2024 was the break: Health Care Benefits adjusted operating income fell from $5,553 million to $307 million — a 94% collapse — on Medicare Advantage utilisation and Part D. Adjusted EPS fell 38% to $5.42. The Company recorded approximately $1.2 billion of restructuring charges, replaced the CEO, and added four directors under investor pressure.

FY2025 was bifurcated: Adjusted operating income rose 20.6% to $14.4 billion and adjusted EPS rose 24.5% to $6.75, while GAAP operating income fell 45.3% to $4.66 billion. The gap of $9.8 billion between GAAP and adjusted operating income is the largest in the Company's history and comprises: $5,725 million goodwill impairment, $1,976 million intangible amortisation, $1,220 million legacy litigation charges, $320 million opioid litigation charge, $288 million Accountable Care loss, $117 million integration costs, $83 million clinic closure charge, and smaller items. The effective tax rate fell to 19.1% because of an approximately $1.9 billion worthless-stock deduction arising from the Omnicare bankruptcy — an extraordinary, non-repeating benefit that flattered GAAP net income by roughly $1.51 per share.

An investor reading GAAP alone would see FY2025 net income of $1.77 billion on $402 billion of revenue, a 0.44% net margin — the worst in at least a decade. An investor reading adjusted EPS alone would see 24.5% growth. Both are true; neither is sufficient.

Balance sheet

Balance sheet commentary. Three facts dominate.

First, goodwill and intangibles of $110.99 billion at 31 December 2025 exceed total shareholders' equity of $75.38 billion by 47%. Tangible book value is deeply negative. Every remaining dollar of goodwill on the Health Care Delivery unit is a live impairment candidate — the FY2025 charge took $5.7 billion but did not eliminate the unit's carrying value.

Second, working capital is structurally negative — approximately -$14.0 billion at FY2025 — because pharmacy claims and discounts payable ($26.3 billion) plus health care costs payable ($15.4 billion) plus accounts payable ($17.6 billion) fund the business. This is normal for the model but means the current ratio of 0.84 is not a distress signal.

Third, deleveraging is real but slow. Total debt fell from $66.27 billion to $64.57 billion during FY2025 and to $61.41 billion at 30 June 2026. Management reported a leverage ratio of 3.84x at 31 March 2026, improving.

At 30 June 2026 the balance sheet had strengthened materially: cash of $11,329 million, total debt of $61,410 million, total shareholders' equity of $79,899 million, and goodwill unchanged at $85,478 million with intangibles at $24,644 million.

Cash flow

Cash flow commentary. Operating cash flow fell 50% from $18.3 billion in FY2021 to $9.1 billion in FY2024 before recovering to $10.6 billion in FY2025. That is the cleanest single indicator of what has happened to this business — GAAP earnings volatility can be argued about, but cash conversion cannot. The recovery in FY2025 was partly a working-capital timing benefit: management explicitly reduced FY2026 operating cash flow guidance to at least $9.0 billion (from at least $10.0 billion) at the February 2026 results, citing payments that shifted from 2026 into late 2025. That guidance was then raised twice during 2026 — to at least $9.5 billion in May and to at least $11.5 billion in August — on genuine underlying improvement.

Capital allocation has been decisively reordered. Buybacks went from $5.0 billion in FY2023 to zero in FY2025. The dividend has been held flat at $0.665 per quarter since the 2024 increase, meaning three consecutive years of a frozen dividend. Total capital returned fell from $8.05 billion in FY2023 to $3.40 billion in FY2025. Every incremental dollar is going to deleveraging.

H1 2026 operating cash flow of $10,594 million against $6,453 million in H1 2025 represents a 64% increase, with approximately $6.3 billion generated in Q2 2026 alone versus $1.9 billion in the prior-year quarter.

Ratio analysis: notes and sources

(All ratios computed by the analyst. GAAP EBITDA = GAAP operating income plus depreciation and amortisation. Adjusted EBITDA = adjusted operating income plus depreciation excluding intangible amortisation, which was $1,976 million in FY2025 and $2,025 million in FY2024. Averages of opening and closing balances used for ROE and ROA.)

Cash conversion cycle. Not meaningfully computable for CVS on a conventional basis: the business carries $19.2 billion of retail inventory against $26.3 billion of pharmacy claims payable and $15.4 billion of health care costs payable, giving a structurally negative cycle. Days claims payable — the relevant analogue for the insurance business — was 38.9 days at 31 December 2025, 42.9 at 31 March 2026 and 41.7 at 30 June 2026.

ROIC. Not meaningfully computable from disclosed data without allocating the Aetna float. Directionally: adjusted operating income of $14.4 billion against invested capital of roughly $140 billion (equity plus total debt) implies a pre-tax adjusted ROIC around 10%, against a weighted average cost of capital that is plausibly 7–8%. On a GAAP basis, ROIC is comfortably below cost of capital. Morningstar's published no-moat rating on CVS rests explicitly on this point, citing a history of "giving away economic profitability through acquisitions."

Interim 2026 results: notes and sources

(Q1 2026 revenue and operating income shown as reported in the Q1 2026 release; H1 figures from the Q2 2026 release, which is the authoritative reconciliation.)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total revenues (USD Mn)

292,111322,467357,776372,809402,067

Revenue growth (%)

8.7110.3910.954.207.85

Gross profit, computed (USD Mn)

n.v.

54,50054,43051,40155,362

Operating income, GAAP (USD Mn)

13,1937,95513,7438,5164,660

Adjusted operating income (USD Mn)

n.v.

n.v.

17,38311,97614,443

Interest expense (USD Mn)

2,5032,2872,6502,9583,119

Income before income tax provision (USD Mn)

10,420

n.v.

11,1556,1482,136

Income tax provision (USD Mn)

2,522

n.v.

2,8081,562408

Effective tax rate (%)

24.2025.9025.1025.4019.10

Net income attributable to CVS Health (USD Mn)

7,9104,1498,3444,6141,768

Basic EPS (USD)

6.003.166.493.671.40

Diluted EPS (USD)

5.953.146.473.661.39

Adjusted EPS (USD)

8.408.698.745.426.75

Dividends declared per share (USD)

2.002.202.422.662.66

Weighted average diluted shares (millions)

1,3301,3211,2901,2621,271

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin metric (%)

Margin metric (%)FY2021FY2022FY2023FY2024FY2025

Gross margin, computed

n.v.

16.9015.2113.7913.77

GAAP operating margin

4.522.473.842.281.16

Adjusted operating margin

n.v.

n.v.

4.863.213.59

Net margin

2.711.292.331.240.44

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (USD Mn)

232,999228,275249,728253,215253,538

Cash and cash equivalents (USD Mn)

9,40812,9458,1968,5868,453

Short-term investments (USD Mn)

n.v.

n.v.

n.v.

2,4072,145

Accounts receivable, net (USD Mn)

n.v.

n.v.

n.v.

36,46939,779

Inventories (USD Mn)

n.v.

n.v.

n.v.

18,10719,246

Total current assets (USD Mn)

n.v.

n.v.

n.v.

68,64574,714

Long-term investments (USD Mn)

n.v.

n.v.

n.v.

28,93432,669

Property and equipment, net (USD Mn)

n.v.

n.v.

n.v.

12,99313,083

Operating lease right-of-use assets (USD Mn)

n.v.

n.v.

n.v.

15,94414,973

Goodwill (USD Mn)

79,12178,15090,70091,27285,478

Intangible assets, net (USD Mn)

n.v.

n.v.

n.v.

27,32325,508

Total current liabilities (USD Mn)

n.v.

n.v.

n.v.

84,60988,692

Short-term debt (USD Mn)

002002,1190

Current portion of long-term debt (USD Mn)

4,2051,7782,7723,6244,068

Long-term debt (USD Mn)

51,97150,47658,60060,52760,502

Total debt (USD Mn)

56,17652,25461,57266,27064,570

Net debt, computed (USD Mn)

46,76839,30953,37657,68456,117

Total shareholders' equity (USD Mn)

75,38171,07076,46175,73075,382

Total liabilities (USD Mn)

n.v.

n.v.

n.v.

177,485178,156

Goodwill and intangibles as share of equity (%)

n.v.

n.v.

n.v.

156.8147.2

Working capital, computed (USD Mn)

n.v.

n.v.

n.v.

-15,964-13,978

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Net cash provided by operating activities (USD Mn)

18,26516,17713,4269,10710,639

Purchases of property and equipment (USD Mn)

2,5202,727

n.v.

2,7812,832

Free cash flow, computed (USD Mn)

15,74513,450

n.v.

6,3267,807

Depreciation and amortisation (USD Mn)

n.v.

n.v.

n.v.

4,5974,606

Acquisitions, net of cash acquired (USD Mn)

n.v.

n.v.

n.v.

95436

Dividends paid (USD Mn)

2,6252,8823,0513,3733,397

Share repurchases (USD Mn)

03,5005,0003,0230

Total capital returned (USD Mn)

2,6256,3828,0516,3963,397

Proceeds from issuance of long-term debt (USD Mn)

n.v.

n.v.

n.v.

7,9133,969

Repayments of long-term debt (USD Mn)

n.v.

n.v.

n.v.

4,7733,629

Net cash used in investing activities (USD Mn)

n.v.

n.v.

n.v.

7,6135,871

Net cash used in financing activities (USD Mn)

n.v.

n.v.

n.v.

1,1354,940

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025

Return on equity, GAAP (%)

6.072.35

Return on assets, GAAP (%)

1.830.70

Return on equity on adjusted income (%)

9.0011.37

Current ratio

0.810.84

Total debt to equity

0.880.86

Net debt to equity

0.760.74

Net debt to GAAP EBITDA, computed

4.406.06

Net debt to adjusted EBITDA, computed

3.513.29

Interest coverage on GAAP operating income

2.881.49

Interest coverage on adjusted operating income

4.054.63

Asset turnover

1.481.59

Goodwill plus intangibles to total assets (%)

46.8343.78

Income Statement and Per-Share Data

Metric (USD Mn except per share)Q1 2025Q1 2026Q2 2025Q2 2026H1 2025H1 2026

Total revenues

94,588100,42698,915106,096193,503206,522

Operating income

3,3744,6802,3814,7035,7559,383

Adjusted operating income

4,5795,1503,8085,1578,38710,307

Net income attributable to CVS Health

1,7792,9431,0212,9792,8005,922

Diluted EPS (USD)

1.412.300.802.312.214.61

Adjusted EPS (USD)

2.252.571.812.584.065.16

Premium revenue by business (USD Mn)

Premium revenue by business (USD Mn)FY2024FY2025

Government

88,433103,362

Commercial

34,41631,387

Growth rate (%)

Growth rate (%)FY2025

Government premiums

16.88

Commercial premiums

-8.80

Channel revenue (USD Mn)

Channel revenue (USD Mn)FY2024FY2025

Pharmacy network

91,650101,775

Mail and specialty

70,87779,334

Other

10,7939,296

Net investment income

28520

Growth rate (%) — Pharmacy network

Growth rate (%)FY2025

Pharmacy network

11.05

Mail and specialty

11.93

Other

-13.87

Business Lines

Line (USD Mn)FY2024FY2025

Pharmacy

100,687115,510

Front store

21,52221,459

Other

2,2912,398

Growth rate (%) — Pharmacy

Growth rate (%)FY2025

Pharmacy

14.72

Front store

-0.29

Other

4.67

Business Lines — Government premiums

LineDirectionCause

Government premiums (+16.9% FY2025)

Fastest growing

Inflation Reduction Act redesign of Medicare Part D shifted claim liability from the government to plans, inflating gross premium revenue without proportionate margin; Medicare Advantage rate increases

Retail pharmacy (+14.7% FY2025)

Fast growing

Drug mix (GLP-1 and specialty brand inflation), increased utilisation, and incremental volume from the Rite Aid prescription file acquisitions completed in Q3 2025

Mail and specialty (+11.9% FY2025)

Fast growing

Specialty drug mix and brand inflation

Front store (-0.3% FY2025, -0.3% FY2024)

Declining

Structural erosion of convenience retail to e-commerce and mass merchants; store closures

Commercial premiums (-8.8% FY2025, -21.8% H1 2026)

Sharply declining

Deliberate margin-led repricing, loss of Insured Commercial members to ASC, and the exit of the individual public exchange business effective January 2026

Health Services "Other" revenue (-13.9% FY2025)

Declining

Divestiture of MSSP operations and wind-down of ACO REACH

Standalone Medicare PDP membership (-17.2% FY2025)

Sharply declining

Pricing discipline in a Part D market disrupted by the IRA redesign; membership fell from 4.88 million to 4.04 million and to 3.87 million by 30 June 2026

Valuation Snapshot

MetricValueAs of

Share price (USD)

95.35

14 August 2026

Share price (USD)

104.42

4 August 2026 close, the day before Q2 results

Share price (USD)

approximately 94.76

5 August 2026 premarket, following the Q2 call

Share price (USD)

76.53

9 December 2025, Investor Day

Market capitalisation (USD Bn)

121.9

14 August 2026

Market capitalisation (USD Bn)

121.6

12 August 2026

Market capitalisation (USD Bn)

126.8

5 August 2026

Market capitalisation (USD Bn)

137.5

24 July 2026

Market capitalisation (USD Bn)

136.4

23 July 2026

Shares outstanding (millions)

1,272.2

4 February 2026

Public float (USD Bn)

86.4

30 June 2025

Share Price & Returns

PeriodReturn / changeSource basis

2025 year to date, as of 20 November 2025

+77.8%

InvestingPro, cited in contemporaneous coverage

Trailing 12 months, market cap, as of 5 August 2026

+62.7%

stockanalysis.com

Trailing 12 months, market cap, as of 12 August 2026

+46.4%

financecharts.com

Trailing 30 days, market cap, as of 12 August 2026

-10.0%

financecharts.com

5-year context

Market capitalisation of $121.6–137.5bn in 2026 against a 1998 base of $19.55bn

stockanalysis.com

Valuation Snapshot by Multiple

MultipleValueBasis

Trailing P/E

25.0

$95.35 against trailing twelve-month GAAP EPS of approximately $3.81

Forward P/E on 2026 guided adjusted EPS

11.9

$95.35 against the $8.00 guidance midpoint

Forward P/E on 2027 consensus adjusted EPS

11.4

$95.35 against a pre-Q2 consensus of $8.37; this consensus predates the guidance raise and the 2027 Caremark commentary and will move

Price to book

1.20

$121.9bn market cap against $79.9bn total shareholders' equity at 30 June 2026

Enterprise value (USD Bn)

approximately 172.0

Market cap $121.9bn plus total debt $61.4bn less cash $11.3bn, at 30 June 2026

EV / sales on 2026 guided revenue

0.42

Against at least $414bn

EV / adjusted EBITDA

approximately 8

Against an annualised H1 2026 adjusted operating income run-rate of roughly $20bn plus depreciation ex-intangible amortisation of roughly $2.7bn; approximate

Dividend yield

2.81%

$2.66 annualised against $95.35

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025FY2026E

Quarterly dividend per share (USD)

0.5000.5500.6050.6650.6650.665

Annual dividend per share (USD)

2.002.202.422.662.662.66

Dividends paid (USD Mn)

2,6252,8823,0513,3733,397—

Payout ratio on adjusted EPS (%)

23.825.327.749.139.433.3

Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025H1 2026

Share repurchases (USD Mn)

03,5005,0003,02300

Credit Ratings

AgencyLong-term ratingOutlookNote

Moody's Ratings

Baa3

Stable

The final investment-grade notch. Historically the Company disclosed Baa2 in its filings through at least mid-2024; the Baa3 designation is from a 2026 third-party compilation

S&P Global Ratings

BBB

Stable

S&P revised the outlook to negative in August 2024 and published a further outlook revision in May 2026; the direction of the May 2026 action was not confirmed in this compilation

Fitch Ratings

BBB

Negative

Per 2026 third-party compilation

Commercial paper

P-2 (Moody's) / A-2 (S&P)

——

Debt metric

Debt metricFY2024FY2025H1 2026

Short-term debt (USD Mn)

2,11900

Current portion of long-term debt (USD Mn)

3,6244,0681,958

Long-term debt (USD Mn)

60,52760,50259,452

Total debt (USD Mn)

66,27064,57061,410

Cash and cash equivalents (USD Mn)

8,5868,45311,329

Net debt (USD Mn)

57,68456,11750,081

Interest expense (USD Mn)

2,9583,119

1531 (H1)

Management-reported leverage ratio

——

3.84x at 31 March 2026

Institution Details

InstitutionActionTarget (USD)Date

Evercore ISI

Target lowered

125

6 August 2026

UBS

Target raised from 115

122

early August 2026

Baird

Target raised from 94

107

6 August 2026

Undisclosed (via TipRanks)

Buy reiterated

110

6 August 2026

Undisclosed (via TipRanks)

Buy reiterated

106

6 August 2026

Morgan Stanley

Buy maintained

—

9 August 2026

Wells Fargo

Buy maintained

—

10 August 2026

J.P. Morgan

Buy maintained

—

11 August 2026

RBC Capital

Buy maintained

—

6 August 2026

Morningstar

No-moat rating; EPS estimates at the top end of management targets

—

February 2026

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance and consensus

MetricFY2025 actualFY2026 guidance (August 2026)Implied change
Total revenues (USD bn)402.1at least 414.0at least +3.0%
GAAP diluted EPS (USD)1.396.84 to 7.04+392% to +406%
Adjusted EPS (USD)6.757.90 to 8.10+17.0% to +20.0%
Cash flow from operations (USD bn)10.6at least 11.5at least +8.5%
Weighted average diluted shares (millions)1,2711,289+1.4%

Medium-term: mid-teens adjusted EPS CAGR through 2028 from the FY2025 base of $6.75, implying adjusted EPS approaching $10.30 by 2028. Health Care Benefits full-year 2026 adjusted operating income was guided at Q1 to approximately $4.00–$4.34 billion.

Consensus (pre-Q2, July 2026): adjusted EPS of $7.44 for 2026 and $8.37 for 2027. Both figures now trail management's own guidance and will be revised upward for 2026; the 2027 number is the contested one.

Bull case

1. The Aetna recovery is ahead of plan and mechanical, not speculative. The medical benefit ratio has moved from 92.5% (FY2024) to 91.2% (FY2025) to 86.0% (H1 2026). Health Care Benefits adjusted operating income has moved from $307 million to $2,939 million to $5,467 million in H1 2026 alone. Management raised full-year adjusted EPS guidance by $0.30 in May and a further $0.60 in August, and raised operating cash flow guidance from at least $9.0 billion to at least $11.5 billion across the same period. Two of these raises followed quarters in which the Company retained its explicit "cautious view" language — the guidance is being set conservatively and beaten.

2. CVS is the last national retail pharmacy standing, and it is being handed share. Rite Aid has liquidated. Walgreens was taken private in August 2025, split into five entities, had its ratings withdrawn and is closing 1,200 stores. CVS acquired Rite Aid prescription files for a fraction of what a store-build programme would cost, absorbed approximately 9 million patients, and delivered same-store prescription volume growth of 8.0% in FY2025 and 6.9% in H1 2026 — the best retail script growth in the sector. Approximately 28.5% of all US retail prescriptions now flow through CVS, and 85% of Americans live within ten miles of a store.

3. Regulatory uncertainty has been converted into a known compliance timetable, and the valuation has not reflected it. The FTC insulin case — the single largest overhang on the PBM for two years — is settled, with no fine, no admission of wrongdoing, and core requirements not effective until 1 January 2028. The countersuit is dismissed. The settlement also resolved outstanding FTC investigations into rebate, pharmacy network, contract and vertical integration issues. At roughly 12x guided 2026 adjusted EPS with a 2.8% dividend and $11.5 billion of operating cash flow, CVS is priced as though the PBM is about to be broken up. It has just been given a compliance path instead.

Bear case

1. The 2027 Caremark problem is real, and management raised it themselves. The stock fell 6–9% on 5 August 2026 on a quarter that beat consensus adjusted EPS by roughly 40% — because management flagged expected PBM membership declines in 2027. Tyson Foods left for Rightway in 2024. Blue Shield of California moved core services to Prime Therapeutics in 2025. Health Services adjusted operating income was $7,357 million in FY2023, $7,243 million in FY2024 and $7,151 million in FY2025 — three consecutive years of decline in the segment that is supposed to fund the enterprise. H1 2026 growth was 1.4%. The FTC consent order's delinking requirement, effective 1 January 2028, removes a rebate-capture mechanism that has historically been a material profit source, and the Company has not quantified the impact.

2. GAAP earnings are not close to adjusted earnings, and the gap is structural. FY2025 GAAP operating income was $4,660 million against adjusted operating income of $14,443 million — a $9.8 billion difference. GAAP net income of $1,768 million included a $483 million deconsolidation gain and an approximately $1.9 billion worthless-stock tax benefit worth $1.51 per share; without them the Company would have posted a GAAP loss on $402 billion of revenue. Intangible amortisation alone runs at approximately $1,730 million a year and is guided to continue into 2026. Goodwill and intangibles of $110.99 billion against $75.38 billion of equity mean tangible book value is deeply negative and a second impairment of the Health Care Delivery unit — which has already absorbed $5.7 billion — remains live while the business is targeted only at "breakeven."

3. The earnings recovery is single-source, non-repeatable in part, and running into a rate and ratings headwind. Every dollar of the $1,920 million H1 2026 adjusted operating income improvement came from Health Care Benefits; Health Services and Pharmacy & Consumer Wellness were flat and Corporate/Other deteriorated by $311 million. Within Health Care Benefits, $1.2 billion of favourable prior-year reserve development in H1 2026 and approximately $500 million (140 basis points of MBR) of favourable prior-year development and risk adjustment items in Q2 alone are not recurring sources. Meanwhile, Medicare Advantage star ratings deteriorated from 88% to 81% of members in 4.0+ star plans, reducing 2027 bonus revenue; CMS is now auditing every MA contract every payment year; the Medicare Drug Negotiation Program expands from 2026; Medicaid funding is contracting under the 2025 legislation; and CVS carries the last investment-grade notch at Moody's with a reported negative outlook at Fitch and $56–61 billion of net debt.

Catalysts and monitorables — next twelve months

CatalystTimingWhat to watch
Q3 2026 resultsLate October / early November 2026Whether the $7.90–$8.10 range is raised a third time; the composition of any beat between underwriting and reserve development
Caremark 2027 selling season outcomesQ3–Q4 2026Named client wins and losses; the specific quantum of the flagged membership decline
Eli Lilly GLP-1 transparent pricing launchEarly Q4 2026Uptake in the CVS Health app; whether the $29 MinuteClinic visit converts to dispensing volume; competitive response from Amazon Pharmacy
2027 Medicare Advantage rate final noticeApproximately April 2027; advance notice issued 26 January 2026The 2026 industry average was +7.16% including risk-score trend; the 2027 setting determines whether the margin recovery is fundable
2027 star ratingsOctober 2026Recovery or further erosion from the 81% level; this determines 2028 bonus payments
Q4 2026 goodwill impairment testingQ4 2026 / February 2027Whether the residual Health Care Delivery carrying value survives a second test
Return of share repurchasesAny quarterThe clearest signal that management considers deleveraging complete; would also address the 1.4% share count creep
Dividend actionDecember 2026 / January 2027A fourth consecutive year at $0.665 would confirm continued balance-sheet priority; an increase would signal confidence
Credit rating actionsOngoingAny Moody's action from Baa3 is binary for the credit; Fitch outlook resolution
Permanent Pharmacy and Consumer Wellness presidentOngoingThe segment has been run on an interim basis by a Senior Vice President
CMS RADV appeal outcome2026–2027CMS has appealed the September 2025 vacatur of the 2023 RADV Final Rule
PBM structural separation legislationOngoingThe Tennessee statute and its Sixth Circuit challenge; whether other states follow
Oak Street clinic closuresThrough 2026Execution against the $83 million charge; whether further closures are announced
2026 full-year results and 2027 guidanceFebruary 2027The single most important event in the window: the first formal quantification of the 2027 Caremark headwind against the mid-teens CAGR commitment

Analyst verdict

CVS Health at $95 is a company that has been fixed operationally but not yet structurally, priced by a market that understands the distinction better than the guidance does.

The operational fix is not in doubt. Aetna's medical benefit ratio has fallen 650 basis points in eighteen months, Health Care Benefits adjusted operating income has gone from $307 million to a $5.5 billion first half, operating cash flow has been guided up twice from at least $9.0 billion to at least $11.5 billion, and the retail pharmacy business is taking share from a collapsing competitive set at almost no capital cost. Management under Joyner and Newman has beaten its own guidance in three consecutive quarters while explicitly maintaining a cautious posture. That is what competent execution looks like, and it deserves credit.

The structural question is untouched. Health Services adjusted operating income has now declined in three consecutive years, and management itself introduced 2027 Caremark membership declines on the Q2 call — costing the stock nine percent on a forty percent earnings beat, which tells you precisely where the market's attention sits. The FTC consent order's delinking requirement lands on 1 January 2028 and has not been quantified. Goodwill of $85.5 billion still sits on a balance sheet with $75–80 billion of equity, and the health care delivery unit that absorbed a $5.7 billion impairment is being asked only to break even. Adjusted EPS is still 20% below its FY2021 level after four years of 8% revenue compounding — the clearest evidence available that this business converts scale into revenue rather than profit.

The mid-teens CAGR to 2028 therefore requires two things: that Aetna's normalisation holds without the reserve development that has flattered recent quarters, and that Caremark stops shrinking. The first looks achievable. The second is unproven, and 2028 is precisely when the FTC order bites.

At roughly 12x guided 2026 adjusted earnings with a 2.8% yield, a 56-year dividend record and $11.5 billion of operating cash flow, the risk is priced with reasonable honesty — which is why the sell-side target range of $106 to $125 skews bullish. This is a credible recovery story with a genuine, dated, unquantified 2027–2028 problem attached. The February 2027 guidance event, not the next quarter, is where the thesis will be settled.


APPENDIX: SOURCE REGISTER

  • CVS Health Corporation, Form 10-K for the fiscal year ended 31 December 2025 — Filed 10 February 2026 — Business description, segments, products, competition, government regulation, human capital, intellectual property, footprint, star ratings, membership, network scale

  • Q4 and Full-Year 2025 Earnings Release, Exhibit 99.1 — 10 February 2026 — FY2024 and FY2025 income statement, balance sheet, cash flow, segment revenues and adjusted operating income, non-GAAP reconciliations, 2026 initial guidance

  • Q2 2026 Earnings Release, Exhibit 99.1 to Form 8-K — 5 August 2026 — Q2 and H1 2026 results, segment detail, membership, balance sheet at 30 June 2026, raised 2026 guidance

  • Q1 2026 Earnings Release and earnings call transcript — 6 May 2026 — Q1 2026 results, first guidance raise, leverage ratio, parent cash

  • Form DEF 14A, 2026 Annual Meeting — Filed 3 April 2026 — Board composition, committees, independence, governance developments, executive compensation, stockholder engagement, 2025 performance highlights

  • Form 8-K, 2026 Annual Meeting voting results — May 2026 — Meeting outcomes and quorum

  • 2025 Investor Day press release and Form 8-K — 9 December 2025 — Strategy pillars, 2026 guidance, mid-teens CAGR commitment, footprint and relationship statistics

  • CVS Health leadership page — Accessed August 2026 — Current Executive Leadership Team roster and titles

  • CVS Health press releases — Various, 2025–2026 — Chair appointment, dividend declarations, GLP-1 and Eli Lilly collaboration, Omnicare Chapter 11

  • Federal Trade Commission press release on the Caremark settlement — July 2026 — Consent order terms

  • Healthcare Dive, AJMC, Buchanan Ingersoll & Rooney, Truveris — 2026 — FTC settlement chronology and terms

  • CNBC, Investing.com, Barchart, Morningstar, Seeking Alpha, Quartz — 2025–2026 — Market reaction, consensus estimates, analyst actions

  • stockanalysis.com, macrotrends, companiesmarketcap, financecharts, Robinhood, Yahoo Finance, Google Finance — August 2026 — Share price, market capitalisation, dividend yield, historical revenue and net income

  • stock-analysis-on.net — Compiled from Forms 10-K through FY2024 — FY2021–FY2023 segment revenue and operating income cross-checks

  • Fierce Healthcare, Insurance Business, Healthcare Finance News, UnitedHealth Group FY2025 results — February 2026 — Peer FY2025 revenue and profitability

  • Becker's Payer Issues / Becker's Hospital Review — 3 April 2026 — NEO compensation table cross-check

  • Healthcare Digital, Sustainability Magazine, Net Zero Tracker, CVS Health impact pages, DitchCarbon, KnowESG — 2024–2026 — ESG targets, progress and third-party ratings

  • Revelio Labs — March 2026 — Third-party headcount and geographic workforce estimates

  • Hartford Business Journal, Westfair, TheStreet — 2025–2026 — WARN notices and Aetna workforce reductions

  • investmentgrade.com — 2026 — Third-party credit rating compilation

  • WallStreetZen, Fintel, tickergate — 2026 — Ownership estimates

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleNotes

J. David Joyner

Chairman and Chief Executive Officer

Age 61. President and CEO since 17 October 2024; Chair since 1 January 2026. Previously EVP and President of Pharmacy Services from January 2023; advisor to health care enterprises September 2020 – January 2023; EVP Sales and Account Services, CVS Caremark 2004–December 2019. Began his career at Aetna in 1986, joined Caremark Prescription Services in 1993. Nearly 40 years in health care and PBM. B.S., Rawls College of Business, Texas Tech University.

Brian O. Newman

Executive Vice President and Chief Financial Officer

CFO since May 2025 (designate from 21 April 2025). Previously EVP and CFO of United Parcel Service August 2019 – May 2024; 26 years at PepsiCo in senior finance roles across Europe, Asia, North and South America.

Prem Shah

Executive Vice President and Group President

Group President since 6 November 2024, responsible for operational performance and integrated value creation across CVS Caremark, CVS Pharmacy and Health Care Delivery. Joined CVS Health 2013; previously EVP and Chief Pharmacy Officer and President, Pharmacy and Consumer Wellness.

Steve Nelson

Executive Vice President and President, Aetna

Age 67. Appointed November 2024. Previously CEO of ChenMed (February–August 2024); former CEO of UnitedHealthcare, a division of UnitedHealth Group.

Tilak Mandadi

Executive Vice President, Ventures and Chief Experience and Technology Officer

Age 62. In role since July 2022. Previously Chief Strategy Officer of MGM Resorts International (2021–2022) and EVP Digital and Global CTO of Disney Parks, Experiences and Products (2013–2021).

Sree Chaguturu, MD

Executive Vice President and President of Health Care Delivery

Oversees Oak Street Health, Signify Health and MinuteClinic.

Amy Compton-Phillips, MD

Executive Vice President and Chief Medical Officer

Clinical strategy across the enterprise.

Ed DeVaney

Executive Vice President and President, Caremark

PBM leadership.

Katerina Guerraz

Executive Vice President, CVS Health, and Chief Operating Officer, Aetna, and President of Medicaid, Aetna

Combined operating and Medicaid leadership.

Sam Khichi

Executive Vice President, Corporate Affairs and Chief Legal Officer

Legal, compliance and public affairs.

Heidi Capozzi

Executive Vice President and Chief People Officer

Human capital strategy; reports to the CEO with Board oversight.

Len Shankman

Executive Vice President and President, Pharmacy Services

Pharmacy services leadership.

Siddharth (Sid) Tenneti

Senior Vice President and Interim President, Pharmacy and Consumer Wellness

Interim leadership of the retail segment as of August 2026.

Larry McGrath

Executive Vice President, Capital Markets

Investor relations and capital markets; hosts earnings calls.

Kristina V. Fink

Senior Vice President, Corporate Secretary and Chief Governance Officer

Signed the 2026 notice of annual meeting.

Directors' Remuneration

ExecutiveSalary (USD)Stock awards (USD)Option awards (USD)Non-equity incentive (USD)All other (USD)Total (USD)

J. David Joyner, President and CEO

1,500,00014,499,93104,695,900453,60921,214,084

Prem Shah, EVP and Group President

1,100,0007,199,9201,799,9933,013,000266,29713,379,210

Steve Nelson, EVP and President, Aetna

1,000,0005,799,9151,449,9942,988,000349,20111,587,110

Tilak Mandadi, EVP Ventures and CETO

1,000,0005,599,9651,399,9962,561,000416,75510,977,716

Brian O. Newman, EVP and CFO

696,9705,599,9501,399,9891,562,000161,5999,420,508

Thomas F. Cowhey, former EVP and CFO

420,8304,400,00000791,2406,720,000

Board of Directors

DirectorPrincipal occupationAgeDirector sinceIndependentCommitteesOther public boards

Fernando Aguirre

Former Chairman, President and CEO, Chiquita Brands International

68

November 2018

Yes

Audit (Chair); MP&D

2 (Barry Callebaut AG; Synchrony Financial)

Jeffrey R. Balser, M.D., Ph.D.

President and CEO, Vanderbilt University Medical Center; Dean, Vanderbilt University School of Medicine

64

September 2022

Yes

Health Services & Technology (Chair); Audit; Executive

—

C. David Brown II

Partner, Nelson Mullins Riley & Scarborough LLP

74

March 2007

Yes

MP&D (Chair); N&CG; PP&EA

—

Alecia A. DeCoudreaux

President Emerita, Mills College at Northeastern University; former Eli Lilly executive

71

March 2015

Yes

HS&T; N&CG

1 (Parnassus Funds)

Anne M. Finucane

Chair, Rubicon Carbon; former Vice Chairman, Bank of America

73

January 2011

Yes

PP&EA (Chair); MP&D; Executive

1 (Williams-Sonoma)

John E. Gallina

Former EVP and CFO, Elevance Health

66

March 2026

Yes

Audit

1 (Arrive AI)

J. David Joyner

President, CEO and Chair, CVS Health

61

October 2024

No (employment)

Executive (Chair); PP&EA

—

J. Scott Kirby

CEO, United Airlines Holdings

58

October 2023

Yes

HS&T; N&CG

1 (United Airlines)

Michael F. Mahoney

Chairman, President and CEO, Boston Scientific

61

November 2023

Yes — Lead Independent Director since March 2025

N&CG (Chair); MP&D; Executive

1 (Boston Scientific)

Leslie V. Norwalk

Strategic Counsel, Epstein Becker & Green; former Acting Administrator, CMS

60

November 2024

No (past expert-witness service in Company litigation)

HS&T; PP&EA

3 (Arvinas; Neurocrine Biosciences; Globus Medical)

Larry M. Robbins

Founder, CEO and Portfolio Manager, Glenview Capital Management

56

November 2024

Yes

Audit; PP&EA

1 (Butterfly Network)

Guy P. Sansone

Co-Founder, Chairman and CEO, H2 Health

61

November 2024

Yes

Audit; N&CG

1 (Pediatrix Medical Group)

Douglas H. Shulman

Chairman and CEO, OneMain Holdings; former IRS Commissioner

58

November 2024

Yes

HS&T; MP&D

1 (OneMain Holdings)

Major Shareholders

HolderReported stake (%)Source and date

BlackRock, Inc.

9.87 (125.92 million shares)

WallStreetZen, early August 2026

The Vanguard Group, Inc.

approximately 9.5

Multiple trackers, 2026

State Street Corporation

approximately 4.1

Third-party compilation, year-end 2025 proxy filings

Glenview Capital Management, LLC

Low single digits; reported as the holder with the largest share of its own assets in CVS

Third-party compilation

Vanguard Total Stock Market Index Fund

Top-10 fund holder

Fintel

Dodge & Cox Stock Fund

Top-10 fund holder

Fintel

Vanguard 500 Index Fund

Top-10 fund holder

Fintel

Washington Mutual Investors Fund

Top-10 fund holder

Fintel

Competitive Landscape

Competitors by Segment

SegmentNamed and identified competitors

Health Care Benefits

UnitedHealthcare (UnitedHealth Group); Elevance Health and the Blue Cross Blue Shield licensee system; The Cigna Group; Humana; Centene; Molina Healthcare; health-system-owned plans; third-party administrators; Original Medicare (explicitly identified by the Company as the largest competitor in Medicare products); start-up and provider-owned plans; Oscar Health; Alignment Healthcare

Health Services (PBM)

The Express Scripts business of The Cigna Group; the Optum Rx business of UnitedHealth Group; Prime Therapeutics (named in the 10-K); MedImpact (named in the 10-K); CarelonRx (Elevance); Navitus; Capital Rx; smaller standalone PBMs

Health Services (care delivery)

Large and medium local and national primary care providers; health-system-affiliated practices; agilon health; Privia Health; ChenMed; One Medical (Amazon); VillageMD; Optum Health

Health Services (in-home evaluations)

Pure-play health risk assessment providers; large payors performing assessments in-house or through multiple vendors

Health Services (MinuteClinic)

Retail health clinics; urgent care; primary care offices

Pharmacy & Consumer Wellness

Walgreens (named in the 10-K); Walmart (named); Amazon (named); supermarkets; discount retailers; independent pharmacies; restrictive pharmacy networks; membership clubs including Costco; infusion pharmacies; mail order dispensing pharmacies; Kroger Health; Mark Cuban Cost Plus Drug Company

Peer Comparison FY2025

MetricCVS HealthUnitedHealth GroupThe Cigna GroupElevance Health

FY2025 revenue (USD Bn)

402.1447.6274.9197.6

FY2025 revenue growth (%)

7.8

approximately 8

11.012.8

FY2025 net income attributable (USD Bn)

1.7712.056.0

n.v.

FY2025 net margin (%)

0.442.692.18

n.v.

FY2025 medical loss / benefit ratio (%)

91.2

89.1 (full year)

n.v.

n.v.

FY2025 adjusted operating income (USD Bn)

14.44

n.v.

n.v.

4.2 (adjusted operating gain)

Owns a top-3 PBM

Yes (Caremark)

Yes (Optum Rx, $154.7bn FY2025 revenue, +16%)

Yes (Express Scripts)

Yes (CarelonRx, sub-scale)

Owns a national retail pharmacy chain

Yes (~9,000 stores)

No

No

No

Owns primary care at scale

Yes (Oak Street, 246 centres)

Yes (Optum Health)

No

Partial (Carelon)

R&D disclosed

No

No

No

No

Share price (11 Aug 2026, USD)

approximately 96

403.27272.45390.41

Recent Developments

--

Company Snapshot

$402,067M

Revenue

300,000

Employees

1996

Founded

SWOT Analysis

Strengths

  • Unmatched physical density. Approximately 9,000 retail locations, more than 1,000 walk-in and primary care clinics, and 85% of Americans within ten miles of a CVS Pharmacy (2025 Investor Day). No competitor in the diversified payor group has any comparable asset.
  • Dispensing scale that converts to purchasing power. 1.81 billion prescriptions filled on a 30-day equivalent basis in FY2025 — approximately 28.5% of all US retail prescriptions — sourced partly through the 50/50 Red Oak Sourcing venture with Cardinal Health.
  • PBM reach of approximately 87–88 million plan members processing 1.90 billion claims in FY2025 across a network of approximately 63,000 pharmacies (34,500 chain, 28,500 independent).
  • Demonstrated underwriting recovery. Health Care Benefits adjusted operating income moved from $307 million (FY2024) to $2,939 million (FY2025) to $5,467 million in H1 2026 alone, with the MBR improving from 92.5% to 91.2% to 86.0% over the same progression.
  • Cash generation has re-accelerated. H1 2026 operating cash flow of $10,594 million against $6,453 million in H1 2025, with approximately $6.3 billion in Q2 2026 alone versus $1.9 billion in the prior-year quarter; full-year guidance raised to at least $11.5 billion from at least $9.5 billion.
  • An unbroken dividend record. The Company has paid a cash dividend every quarter since becoming public, a 56-year streak referenced in Q2 2026 materials, with approximately $880 million returned in Q2 2026 alone.
  • Competitor exit has handed CVS share without capital outlay. The Rite Aid prescription file acquisitions cost a fraction of a store-build programme yet drove 8.0% same-store script growth in FY2025 and absorbed approximately 9 million patients.
  • Regulatory resolution ahead of one competitor. The FTC insulin settlement was finalised in July 2026 with core requirements deferred to 1 January 2028, and the PBMs' countersuit was dismissed by the Eighth Circuit — CVS now has a known compliance runway.

Weaknesses

  • GAAP profitability is minimal. FY2025 net income attributable to CVS Health of $1,768 million on $402,067 million of revenue is a 0.44% net margin, against UnitedHealth's 2.69%.
  • Goodwill and intangibles of $110.99 billion exceed total shareholders' equity of $75.38 billion by 47%. Tangible book value is deeply negative, and the FY2025 impairment did not exhaust the Health Care Delivery carrying value.
  • The 2023 care-delivery acquisitions have destroyed value. A $5,725 million goodwill impairment, an $83 million clinic-closure charge, Oak Street clinic closures in 2026, and a stated ambition of merely "driving towards breakeven."
  • Structural adjusted-EPS decline over five years. Adjusted EPS of $8.40 (FY2021) to $6.75 (FY2025) is a negative CAGR of approximately 5.3% despite 8.31% revenue CAGR.
  • Reliance on non-recurring items to support GAAP results. FY2025 GAAP net income of $1,768 million included a $483 million gain on deconsolidation and an approximately $1.9 billion worthless-stock tax benefit worth $1.51 per share. Excluding these, the Company would have reported a GAAP loss.
  • Front store erosion. Front store revenue fell in both FY2024 (-0.3%) and FY2025 (-0.3%) while pharmacy grew 14.7%, driving segment gross margin from 20.2% to 18.5%.
  • Legal cost has been recurrent, not exceptional. $5.8 billion (2022 opioid), $100 million (FY2024 opioid), $320 million (FY2025 opioid), $1,220 million (FY2025 legacy litigation), $948.8 million (Omnicare judgment). This is a pattern.
  • Leadership instability. Two CEOs and two CFOs since October 2024; the Pharmacy and Consumer Wellness presidency held on an interim basis by a Senior Vice President as of August 2026.

Opportunities

  • Aetna margin has not yet returned to its own historic level. FY2023 Health Care Benefits adjusted operating margin was 5.22%; FY2025 was 2.05% and H1 2026 was 7.44% (seasonally flattered). Full-year normalisation toward 4–5% would add several billion dollars of adjusted operating income.
  • GLP-1 monetisation as a category-defining position. The $29 MinuteClinic visit, the Eli Lilly transparent-pricing collaboration live from early Q4 2026, participation in the CMS Medicare GLP-1 Bridge programme at $50 per month through 2027, and availability of all FDA-approved GLP-1s make CVS the only operator combining prescribing, dispensing, benefit design and pharmacist support in one pathway.
  • AI-driven cost takeout is already measurable. 20–30% reduction in call volume and complex-call handling time; over 20% faster processing on complex manual-review claims via CAM; approximately 90 minutes per Aetna nurse per day released.
  • Biosimilar economics via Cordavis delivered more than $1.5 billion of client savings in 2025 and provide a differentiated supply-side lever as more biologics lose exclusivity.
  • Consolidation of retail pharmacy share. With Walgreens private and closing 1,200 stores and Rite Aid gone, further script-file acquisitions are available at low capital cost.
  • Deleveraging into a re-rating. The leverage ratio improved to 3.84x at Q1 2026 and total debt fell to $61.4 billion by June 2026; a return to buybacks would be a visible signal of balance-sheet normalisation.
  • Signify Health's payor-agnostic position — 46 health plan clients including 24 of the 50 largest MA plans — is a growth asset that is uncorrelated with Aetna's own membership.
  • The mid-teens EPS CAGR target through 2028 implies adjusted EPS near $10.30, and 2026 guidance of $8.00 at the midpoint is already tracking ahead of that path.

Threats

  • Caremark membership loss in 2027. Management's own commentary on the 5 August 2026 call caused a roughly 9% single-day share price decline. Tyson Foods (2024) and Blue Shield of California (2025) have already left.
  • Structural separation legislation. Tennessee has enacted a law breaking up PBM-pharmacy common ownership, challenged in June 2026 by Express Scripts and PCMA. If such laws propagate, the integrated model itself is at risk.
  • CMS RADV audits of every Medicare Advantage contract each payment year, with 2018–2024 expedited, plus DOJ Civil Investigative Demands regarding diagnosis-code submission under Parts C and D. The September 2025 vacatur of the 2023 RADV Final Rule is under appeal by CMS.
  • Star rating deterioration. More than 81% of MA members in 4.0+ star plans for 2026 versus 88% for 2025; plans rated below 4 stars lose quality bonus payments in 2027.
  • Medicare Drug Negotiation Program expansion. First ten drug prices effective 2026, expanding to up to 100 Part B and D drugs by 2031, with mandatory formulary coverage of negotiated drugs — removing formulary leverage.
  • Medicaid funding contraction. The Working Families Tax Cut Act of 2025 reduces Medicaid eligibility and state funding, with direct effect on benefits and payment rates in the 15 states where CVS operates Medicaid plans.
  • Credit rating fragility. Moody's rates CVS Baa3 — the final investment-grade notch — with S&P at BBB stable and Fitch at BBB with a negative outlook per third-party compilation. A single-notch downgrade at Moody's would push the Company to sub-investment grade with a mechanical increase in borrowing costs and a shrinkage of the eligible investor base.
  • New consumer litigation fronts. An August 2026 ruling requires drugmakers and retailers including CVS to face phenylephrine decongestant false-advertising claims; a House Judiciary investigation into specialty pharmacy hub practices was reported in January 2026.
  • Amazon. Explicitly named as a competitor in the 10-K, expanding same-day delivery of Eli Lilly weight-loss drugs in direct competition with CVS's own Lilly arrangement.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Q1 2025Divestiture of MSSP operations; ACO REACH wind-down commencedExit from sub-scale provider enablement; $247m pre-tax loss recorded in Q1
Q1 2025Omnicare False Claims Act jury verdict (April 2025, SDNY) finds Omnicare and CVS Health liable for dispensing practices from 2010 through 2018; damages found only against Omnicare$387m litigation charge recorded in Q1 2025 within Pharmacy & Consumer Wellness
April 2025Closure of the Carefree insurance line of business; 55 layoffsPortfolio pruning
21 April 2025Brian Newman named CFO designateSecond CFO change in under a year
1 May 2025Q1 2025 results: revenue $94.6bn (+7%), adjusted EPS $2.25 (+71.8%); full-year adjusted EPS guidance raised to $6.00–$6.20First clear evidence of Aetna margin recovery
May 2025CMS announces it will audit every Medicare Advantage contract each payment year, with an expedited plan to complete payment years 2018–2024 by early 2026Materially raises risk-adjustment audit exposure across the industry
2 June 2025Thomas Cowhey's CFO role ends; Newman assumes the roleCompleted transition
June 2025Court finds CVS subsidiaries liable in *United States ex rel. Behnke* over PBM direct and indirect remuneration reporting for two clients from 2010 through 2016$291m litigation charge in Health Services; practices since modified
Q2 2025Additional $542m charge for penalties assessed under the False Claims Act in the Omnicare matter; $471m premium deficiency reserve recorded in Group Medicare AdvantageQ2 2025 GAAP diluted EPS falls to $0.80
July 2025$948.8m judgment entered against OmnicareTriggers the Chapter 11 decision
31 July 2025Q2 2025 resultsAdjusted EPS $1.81 despite $833m of legacy litigation charges
August 2025Long-term debt issuanceContributed to a $161m (5.4%) full-year increase in interest expense
August 2025Walgreens Boots Alliance completes its take-private by Sycamore Partners; credit ratings withdrawn; a 1,200-store closure programme beginsThe largest US retail pharmacy competitor exits public markets and shrinks
22 September 2025Omnicare, LLC and 110 affiliates file Chapter 11 in the Northern District of Texas; $110m DIP financing; CVS deconsolidates$483m gain on deconsolidation; approximately $1.9bn worthless-stock tax benefit; removal of long-term care pharmacy from the reported script base
Q3 2025Rite Aid prescription file acquisitions completedApproximately 9 million patients and 3,500+ colleagues absorbed
October 2025CMS releases 2026 Medicare Advantage star ratings: more than 81% of Aetna MA members in 4.0+ star plans and more than 63% in 4.5-star plans, versus 88% at 4.0+ for 2025Determines 2027 bonus payments; a material step down
17 October 2025WARN notice for 72 remote Aetna Medicare/Medicaid programme workers in Kentucky, Michigan and Ohio, effective from 31 December 2025, following the loss of a 2026 contractFirst of a sequence of Aetna reductions
29 October 2025Q3 2025 results: Health Care Benefits adjusted operating income of $314m against a $924m loss in the prior-year quarter; adjusted EPS $1.60 versus $1.09Inflection quarter for the insurance turnaround
September 2025US District Court, Northern District of Texas vacates CMS's 2023 RADV Audit Final Rule; CMS appealsRemoves, for now, the elimination of the fee-for-service adjuster in contract-level RADV audits
20 November 2025Board elects Joyner Chair effective 1 January 2026; new Public Policy and External Affairs Committee created; Farah to remain a directorConsolidation of board and executive leadership
December 2025WARN notice for 164 additional remote workers effective from 15 February 2026Continued Aetna cost reduction
9 December 2025Investor Day: 2025 guidance raised (revenue to at least $400bn; adjusted EPS to $6.60–$6.70), 2026 guidance issued, mid-teens adjusted EPS CAGR through 2028 committedShares rose approximately 3%; stock was up 77.8% year to date
1 January 2026Joyner becomes Chair; Aetna exits all individual public exchange statesGovernance change and a deliberate ~1.0 million member revenue sacrifice for margin
6 January 2026Quarterly dividend of $0.665 declared, payable 2 February 2026Third consecutive year at the same rate
January 2026House Judiciary Committee investigation reported into allegations that CVS shut out rival pharmacy hubsAdds a legislative front to the PBM regulatory picture
4 February 2026Express Scripts becomes the first PBM to settle the FTC insulin caseSets the template CVS would follow
February 2026Trump administration signs a funding bill containing PBM reforms plus hospital-at-home and telehealth extensionsStatutory PBM change enacted
6 February 2026WARN notice: 313 Aetna employees assigned to the Hartford office (17 Connecticut residents) to be separated between 3 April and 31 July 2026, attributed to "operational changes in CVS Health Aetna's Small Group business segment"Roles affected are Small Group sales/account management analysts, underwriting and plan sponsor services
10 February 2026FY2025 results: record revenue $402.1bn (+7.8%); GAAP diluted EPS $1.39; adjusted EPS $6.75 (+24.5%); operating cash flow $10.6bn; 2026 guidance confirmed but operating cash flow guidance cut to at least $9.0bn from at least $10.0bnShares rose approximately 3%
10 February 2026FY2025 Form 10-K filedDiscloses the $5.7bn Health Care Delivery goodwill impairment and the Omnicare deconsolidation accounting
18 March 2026Quarterly dividend of $0.665 declared, payable 4 May 2026Unchanged
19 March 2026John E. Gallina elected to the Board and appointed to the Audit CommitteeAdds a former payor CFO to the audit function
23 March 2026CVS Caremark and FTC staff execute a proposed consent agreement; the parties jointly move to withdraw from adjudication; the Commission halts the insulin litigation pending the processAlso covers outstanding FTC investigations into rebate, pharmacy network, contract and vertical integration issues
3 April 2026DEF 14A filed for the 14 May 2026 Annual MeetingDiscloses 2025 NEO compensation and the board refreshment
17 April 2026Stakeholders urge the Department of Labor to finalise a PBM transparency ruleContinued regulatory pressure on the model
6 May 2026Q1 2026 results: revenue $100.4bn (+6.2%); GAAP diluted EPS $2.30; adjusted EPS $2.57 (+14.2%); adjusted operating income $5.15bn (+12.4%); full-year adjusted EPS guidance raised to $7.30–$7.50 and revenue to at least $405bn; leverage ratio improved to 3.84x; approximately $2.2bn of cash at parent and unrestricted subsidiariesFirst raise of 2026
14 May 2026Annual Meeting: 13 directors elected; Ernst & Young ratified; say-on-pay approved; 2026 Incentive Compensation Plan approved; the stockholder proposal to reduce the written-consent threshold was voted on with the Board recommending against. Quorum of 1,142,802,406 shares. Roger Farah retiresResolution of the 2025 say-on-pay controversy
June 2026Express Scripts and PCMA sue to block a Tennessee law breaking up PBM-pharmacy common ownershipSignals the next legislative battleground; a direct read-across to CVS's structure
12 June 2026FTC announces a proposed settlement with Optum Rx, the last of the three PBMsIndustry-wide resolution
Late June 2026The Eighth Circuit dismisses the PBMs' countersuit against the FTC following the settlementsEnds the constitutional challenge
10 July 2026Quarterly dividend of $0.665 declared, payable 3 August 2026Unchanged; PBM plan members cited at approximately 88 million
July 2026FTC announces the final Caremark settlement, projecting up to $8.5bn of consumer savings over ten years; core requirements to be implemented by 1 January 2028. Terms require delinking manufacturer fees from list price for the standard offering, maintaining GPO activities in the United States, treating low-list-price insulin competitively on standard formularies, offering a standard plan option passing rebates through at point of sale, and permitting plan sponsors to move away from rebate guarantees and spread pricingRemoves a major regulatory overhang; costs are structural rather than financial
5 August 2026Q2 2026 results: revenue $106.1bn (+7.3%); GAAP diluted EPS $2.31 versus $0.80; adjusted EPS $2.58 versus consensus of approximately $1.85; adjusted operating income $5.16bn (+35.4%); HCB MBR 87.4% versus 89.9%; YTD operating cash flow $10.6bn; guidance raised to $7.90–$8.10 adjusted EPS, at least $414bn revenue and at least $11.5bn operating cash flow. Shares fell approximately 6–9% on commentary about expected 2027 Caremark membership declinesThe clearest illustration of the market's forward-looking concern: a very large beat and raise was met with a sharp sell-off
5 August 2026GLP-1 programme revamp and Eli Lilly collaboration announced$29 MinuteClinic virtual visits; transparent Zepbound and Foundayo pricing in the CVS Health app from early Q4 2026
Early August 2026Analyst actions: Baird raises price target to $107 from $94; Evercore ISI lowers to $125 from $130; UBS raises to $122 from $115; Morgan Stanley, Wells Fargo, RBC Capital and J.P. Morgan reiterate Buy ratings with targets including $106 and $110Wide dispersion of targets from $106 to $125
August 2026A US court rules that drugmakers and retailers, including CVS, must face phenylephrine decongestant false-advertising claimsNew consumer-litigation exposure
13 August 2026CVS Health named Overall Winner with four gold awards at the 2026 US Customer Experience AwardsReputational
August 2026CVS begins filling prescriptions for dogs and catsAdjacent category expansion

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Premium Revenue by Business: Government rose from USD 88.4 Bn in FY2024 to USD 103.4 Bn in FY2025.
CVS Health Corp — Premium Revenue by Business
Series (USD Bn)FY2024FY2025
Government88.4103.4
Commercial34.431.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.